Shilpa Medicare Limited has disclosed the conclusion of a USFDA surveillance inspection at its Unit VII, Analytical Services Division in Hyderabad. The inspection, held from September 16 to September 18, 2026, resulted in one procedural observation. The company stated the observation was neither a repeat nor related to data integrity and committed to addressing it within the stipulated timeline. No material impact on business operations is anticipated.
USFDA Inspection Details
Shilpa Medicare Limited has announced the conclusion of a surveillance inspection conducted by the United States Food and Drug Administration (USFDA) at its Unit VII, Analytical Services Division, located in Hyderabad, Telangana. The inspection took place between September 16, 2026, and September 18, 2026.
Inspection Outcome
At the closure of the inspection on September 18, 2026, the USFDA issued a single observation. The company clarified that this observation was procedural in nature and did not represent a repeat of a previous issue nor was it related to data integrity. Shilpa Medicare Limited has affirmed its commitment to addressing this observation and will provide a comprehensive response within the agreed-upon timeframe, including appropriate corrective and preventive actions.
Impact Assessment
Shilpa Medicare Limited does not foresee any material impact on its current business operations or existing supplies from the facility as a result of this inspection outcome. The company reiterated its dedication to maintaining the highest standards of quality and compliance across all its operations.
Source: BSE
